Search PubMed⌕ Search

Biomedical subjects

Peggy Soule Odegard

Publications and source records attributed to Peggy Soule Odegard.

5 recordsLinked to original sources
PubMed2006

Working across the boundaries of health professions disciplines in education, research, and service: the University of Washington experience.

The Institute of Medicine's vision for health professions education specifies working together across professions and schools to provide patient-centered care. Improvement in collaborative preparation of health professionals is seen as central to achieving substantial improvement in the quality of health care. In this article, the authors address one central question: How can medical schools work with other health-sciences schools to promote their educational, research, and service missions? The authors summarize the history of the University of Washington (UW) Health Sciences Center in promoting interprofessional collaboration in education, service and research; analyze the key strategic, structural, cultural and technical elements that have promoted success or served as barriers in the development of the UW Center for Health Sciences Interprofessional Education and Research; and suggest strategies that may be transferable to other institutions seeking to implement an interprofessional health sciences program. These include both top-down and bottom-up authority and function in key working groups, institutional policies such as interprofessional course numbers and shared indirect costs, and development of a culture of interprofessionalism among faculty and students across program boundaries.

Biomedical Research↗
PubMed2005

Inhaled insulin: Exubera.

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of Exubera, a novel, dry-powder formulation of insulin for inhalation, and describe patient satisfaction and quality-of-life data. DATA SOURCES: A MEDLINE search (1966-November 2004) was conducted using the key words inhaled insulin and Exubera for clinical trials limited to human research published in English. BIOSIS Previews and the American Diabetes Association Scientific Abstracts were used for published abstract information. STUDY SELECTION AND DATA EXTRACTION: All available human studies of Exubera were selected for review. References of identified articles were used for additional citations. DATA SYNTHESIS: Exubera is a rapid-acting insulin administered by oral inhalation before meals with long-acting insulin administered subcutaneously once or twice daily for type 1 or 2 diabetes mellitus. Exubera provides similar efficacy and improved patient satisfaction compared with standard subcutaneous insulin therapy (ie, NPH twice daily with regular insulin before meals). Efficacy has also been demonstrated for Exubera when used as adjunctive therapy with oral medications for type 2 diabetes. The onset of Exubera is more rapid and its duration of action is similar to that of regular insulin. To date, Exubera administered before meals with a once-daily long-acting subcutaneous insulin (usually Ultralente) has been compared with standard subcutaneous NPH/regular insulin regimens. Comparison of premeal Exubera plus a basal long-acting insulin analog (eg, glargine) with a regimen of premeal subcutaneous rapid-acting insulin analog (eg, lispro or aspart) plus a basal long-acting insulin analog (eg, glargine) is needed to fully evaluate Exubera. Pulmonary safety appears to be maintained for up to 4 years, although there are no data, as of this writing, on the use of this agent in patients with pulmonary conditions. CONCLUSIONS: Exubera is an effective inhaled insulin for preprandial use in type 1 or 2 diabetes. Improved patient satisfaction over injected insulin increases its potential for use earlier in the treatment of type 2 diabetes.

Administration, Inhalation↗
PubMedDate not supplied

Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.

There are now more than 20 million people in America with diabetes mellitus (DM), and the prevalence of this illness continues to increase especially in those with type 2 DM. Over the past decade, research in the area of DM treatment has focused on pharmacologic approaches to modifying glucose metabolism as well as on lifestyle interventions to prevent and manage DM. Pharmacologic research has been guided by an improved understanding of the human physiology of glucose metabolism, allowing for development of new hormonal drug therapies and improved insulin formulations. As a result, there are several new pharmacologic treatments now available or on the horizon for DM. In this article, the authors review the first of the new hormonal therapies for DM, with a focus on information that will be useful for diabetes educators including the medication actions, side effects, patient counseling points, monitoring, and place in therapy in comparison to existing DM treatments. This series on new therapies has been divided into 3 parts, with this first part devoted to an update on the new incretin mimetic and amylin analog agents recently approved for use in DM. Subsequent parts in this series will focus on the new insulin products and oral therapies available or soon to be available. Cases will be used to assist with understanding the type of patient who will benefit from each of these new therapies.

Amyloid↗
PubMedDate not supplied

Pharmacist provision of language-appropriate education for Asian patients with asthma.

OBJECTIVE: To improve asthma treatment outcomes in Asians living in Seattle and for whom English is a second language. DESIGN: Pre-post design. SETTING: International Community Health Services, Seattle, Washington. PATIENTS: Asians older than 18 years with asthma and whose native language was not English. INTERVENTION: Pharmacists or pharmacy students provided oral and written asthma education in the subject's native language. MAIN OUTCOME MEASURES: Self-reported use of valve-holding chambers and peak flow meters; self-reported asthma symptoms at baseline and 6 months after intervention; number of acute asthma-related (non-routine, non-follow-up) clinic visits during the 6 months before and after the intervention. RESULTS: Thirty-two subjects, aged 42 to 88 years, participated. Subjects demonstrated a reduction in mean number of asthma attacks (3.7 to 1.0, P < .001) and night awakenings (1.4 to 0.3, P < .001). Patient satisfaction with the program was excellent. Spacer and peak flow meter use increased from 7 to 18 subjects (P < .001) and 1 to 14 subjects (P < .0002), respectively. CONCLUSION: Language-appropriate asthma education improved treatment outcome for patients whose native language was not English.

Adult↗